Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
April 25, 2017
Aptose Biosciences to Participate at the Bloom Burton & Co. Healthcare Investor Conference 2017
April 24, 2017
Aptose To Release First Quarter Ended March 31, 2017 Financial Results and Hold Conference Call on May 11, 2017
April 19, 2017
Aptose Biosciences to Present CG’806 Data at AACR Hematologic Malignancies Meeting
March 28, 2017
Aptose Reports Fourth Quarter and Year End 2016 Results
March 28, 2017
Aptose Reports Fourth Quarter and Year End 2016 Results
March 27, 2017
Aptose Announces Planned Departure of Chief Business Officer
March 2, 2017
Aptose to Participate in Upcoming Investor Conferences
February 2, 2017
Aptose Biosciences to Present at Canaccord Genuity Rare Disease Biopharma 1x1 Day
January 23, 2017
Aptose Prioritizes Development of CG’806 First-in Class FLT3/BTK Inhibitor
January 5, 2017
Aptose Biosciences to Present at Biotech Showcase 2017 Conference
December 29, 2016
Aptose Biosciences Provides Update on APTO-253 Development
November 14, 2016
Aptose Biosciences Reports Financial Results for the Third Quarter Ended September 30, 2016
November 10, 2016
Aptose To Release Third Quarter Ended September 30, 2016 Financial Results and Hold Conference Call on November 15, 2016
November 3, 2016
Aptose to Present New APTO-253 Data at the 2016 ASH Annual Meeting
October 13, 2016
Aptose Provides Update on FDA Clinical Hold of APTO-253
September 12, 2016
Aptose Submits Formal Response to Clinical Hold for APTO-253
August 9, 2016
Aptose Biosciences Reports Financial Results for the Second Quarter Ended June 30, 2016
August 9, 2016
Aptose Biosciences to Present at Canaccord Genuity 36th Annual Growth Conference
August 4, 2016
Aptose To Release Second Quarter Ended June 30, 2016 Financial Results and Hold Conference Call on August 9, 2016
June 21, 2016
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
June 21, 2016
Aptose Biosciences Provides Corporate Update in Advance of Annual Meeting of Shareholders
June 8, 2016
Aptose Biosciences and CrystalGenomics Announce Exclusive Agreement for Non-Covalent BTK / FLT3 / AURK Inhibitor
May 10, 2016
Aptose Bioscience Reports Results for the First Quarter Ended March 31, 2016
May 2, 2016
Aptose To Release First Quarter Ended March 31, 2016 Financial Results and Hold Conference Call on May 10, 2016
March 29, 2016
Aptose Reports Fourth Quarter and Year End 2015 Results
March 14, 2016
Aptose To Release Fourth Quarter and Year End December 31, 2015 Financial Results and Hold Conference Call on March 29, 2016
March 3, 2016
Aptose to Participate in Upcoming Investor Conferences
February 18, 2016
Aptose to Present at the 2016 RBC Capital Markets Global Healthcare Conference
December 3, 2015
Moffitt Cancer Center and Aptose Biosciences to Present Data on a Novel Class of Dual-Targeting Bromodomain / Kinase Inhibitors at 57th Annual American Society of Hematology (ASH) Meeting
November 30, 2015
Aptose Biosciences to Participate in Upcoming Investor Conferences
November 20, 2015
Aptose Voluntarily Suspends Clinical Dosing of APTO-253 to Review Drug Manufacturing Processes and Procedures
November 10, 2015
Aptose Biosciences Reports Results for the Third Quarter Ended September 30, 2015
November 10, 2015
Aptose Biosciences Announces Collaborations for New Multi-Targeting Epigenetic Therapeutic Agents
November 5, 2015
Beat AML & Aptose Biosciences Present Data for APTO-253 at the 57th American Society of Hematology (ASH) Annual Meeting
November 5, 2015
Aptose Biosciences to Host Third Quarter Ended September 30, 2015 Financial Results Conference Call and Webcast
October 15, 2015
Aptose Biosciences to Present at the 2015 BIO Investor Forum
September 28, 2015
Aptose Biosciences to Present at 15th Annual Biotech in Europe Forum
August 10, 2015
Aptose Biosciences to Present at Canaccord Genuity 35th Annual Growth Conference
August 4, 2015
Aptose Biosciences Reports Results for the Second Quarter Ended June 30, 2015
July 30, 2015
Aptose Biosciences to Host Second Quarter Ended June 30, 2015 Financial Results Conference Call and Webcast
June 22, 2015
Aptose Biosciences to Present at the 10th Annual JMP Securities Life Sciences Conference
June 10, 2015
Aptose Biosciences announces results of annual and special meeting of shareholders
June 2, 2015
Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia
May 5, 2015
Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015
April 30, 2015
Aptose Biosciences To Host First Quarter Ended March 31, 2015 Financial Results Conference Call and Webcast
March 23, 2015
Aptose Biosciences Announces Appointment of Dr. Michael Andreeff to Scientific Advisory Board
March 23, 2015
Aptose Biosciences to Present at the 12th Annual BIO Asia International Conference
March 5, 2015
Aptose Biosciences to Present at the 27th Annual ROTH Conference
March 3, 2015
Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014
February 26, 2015
Aptose Biosciences To Host Quarter and Seven Month Transition Period Ended December 31, 2014 Conference Call and Webcast
February 25, 2015
Aptose Biosciences to Present at the Cowen & Company 35th Annual Healthcare Conference
February 19, 2015
Aptose Biosciences to Present at the RBC Capital Markets 2015 Global Healthcare Conference
January 20, 2015
Aptose Biosciences Appoints Dr. Bradley Thompson to the Audit Committee
January 13, 2015
Aptose Biosciences Doses First Patient in Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies
January 12, 2015
Aptose Biosciences to Present at Biotech Showcase™ 2015
December 15, 2014
Aptose Biosciences Announces Appointment of Dr. Erich Platzer to Board of Directors
December 9, 2014
Aptose Biosciences Presents APTO 253 Preclinical Data at 56th American Society of Hematology Annual Meeting
December 5, 2014
Aptose Biosciences to Present at Oppenheimer Co 25th Annual Healthcare Conference
December 3, 2014
Aptose Biosciences to Present Preclinical Research Update for APTO-253 at the 56th American Society of Hematology Annual Meeting
November 17, 2014
Aptose Biosciences to Present at The Stifel 2014 Healthcare Conference
November 4, 2014
Aptose Biosciences reports results for the four months ended September 30, 2014
October 30, 2014
Aptose Biosciences To Host Conference Call and Webcast For Four Month Interim Period Ended September 30, 2014
October 21, 2014
Aptose Biosciences Announces Approval for Listing on the NASDAQ Capital Market Shares to Begin Trading Under the Symbol APTO
October 3, 2014
Aptose Biosciences to Present at the 2014 BIO Investor Forum
October 1, 2014
Aptose Biosciences Announces Reverse Stock Split
September 29, 2014
Aptose Biosciences Joins The Leukemia & Lymphoma Society's Groundbreaking Beat AML Research Initiative with Oregon Health & Science University
September 25, 2014
Aptose Biosciences to Present at Upcoming Investor Conferences
September 8, 2014
Aptose Biosciences Recruits Stephen B. Howell, M.D. to Act in the Capacity of Chief Medical Officer
September 2, 2014
Lorus Therapeutics Implements Name Change to Aptose Biosciences
August 19, 2014
Lorus Therapeutics Announces Results of Annual and Special Meeting of Shareholders
August 7, 2014
Lorus Therapeutics to Present at the Canaccord Genuity 34th Annual Growth Conference
July 28, 2014
Lorus Therapeutics Receives FDA Clearance of IND to Initiate LOR-253 Clinical Program in Patients with AML, MDS and other Blood Cancers
July 15, 2014
Lorus Therapeutics Proposes Name Change to "APTOSE BIOSCIENCES" and Share Consolidation for Potential NASDAQ Listing
July 15, 2014
Lorus Therapeutics Reports Results for the Fourth Quarter and Full Year Ended May 31, 2014
July 10, 2014
Lorus Therapeutics To Host Fourth Quarter and Year End 2014 Financial Results Conference Call and Webcast
June 19, 2014
Lorus Therapeutics to Present at the 9th JMP Securities Healthcare Conference
June 16, 2014
Lorus Therapeutics to Present at the 2014 Bloom Burton & Co. Healthcare Investor Conference
June 10, 2014
Lorus Therapeutics Provides Update on Warrants
April 22, 2014
Lorus Therapeutics Inc. Announces Exercise of Over-Allotment Option in Connection with Public Offering of Common Shares
April 10, 2014
Lorus Therapeutics Reports Third Quarter Results for Fiscal 2014
April 10, 2014
Lorus Therapeutics Inc. Completes $25 Million Offering of Common Shares
April 8, 2014
Lorus Therapeutics To Host Third Quarter 2014 Financial Results Conference Call and Webcast
April 8, 2014
TORONTO, ONTARIO--(April 10, 2014) - Lorus Therapeutics Inc. (TSX:LOR) (Lorus") reported financial results for the three and nine months ended February 28, 2014 and provided an update on recent accomplishments. Unless specified otherwise, all amounts are in Canadian dollars.
April 4, 2014
Lorus Therapeutics to Present Data on Lead Compound LOR-253 at AACR Annual Meeting 2014
March 27, 2014
Lorus Therapeutics Inc. Upsizes Overnight Marketed Financing to $25M
March 27, 2014
Lorus Therapeutics Announces Results of Annual and Special Meeting of Shareholders
March 26, 2014
Lorus Therapeutics Inc. Announces $17M Overnight Marketed Financing
March 18, 2014
Lorus Therapeutics Announces the Departure of Its President and Chief Operating Officer
March 5, 2014
Lorus Therapeutics to Present at the 26th Annual ROTH Conference
February 24, 2014
Lorus Therapeutics to Present at the RBC Capital Markets 2014 Global Healthcare Conference
January 13, 2014
Lorus Therapeutics to Present at Biotech Showcase™ 2014
January 8, 2014
Lorus Therapeutics Inc. Announces Exercise in Full of Over-Allotment Option in Connection With Public Offering of Common Shares
January 7, 2014
Lorus Therapeutics Reports Second Quarter Results for Fiscal 2014
December 10, 2013
Lorus Therapeutics Completes $7,001,500 Prospectus Offering of Common Shares
December 5, 2013
Lorus Therapeutics to Present at Oppenheimer & Co. 24th Annual Healthcare Conference
December 4, 2013
Lorus Therapeutics to File Final Prospectus for Equity Offering and Provides Corporate Update
December 2, 2013
Lorus Therapeutics Completes New Executive Management Team
November 22, 2013
Lorus Therapeutics Inc. Upsizes Overnight Marketed Financing to Approximately C$7,001,500 of Common Shares
November 21, 2013
Lorus Therapeutics Inc. Announces C$5,000,000 Overnight Marketed Financing
October 29, 2013
Lorus to Focus LOR-253 Development on AML Based on Genetic Insights Into the Causes of Certain Hematologic Cancers
October 28, 2013
Lorus Therapeutics Appoints New Chief Executive Officer
October 23, 2013
Lorus Therapeutics Postpones Annual Meeting Date
October 15, 2013
Lorus Therapeutics Reports First Quarter Results for Fiscal 2014
October 11, 2013
Lorus Therapeutics Apply to Extend Annual Meeting Date
October 1, 2013
Lorus Therapeutics Announces Presentation of its Phase I Clinical Trial of LOR-253 at the European Cancer Congress
September 26, 2013
Lorus Therapeutics Closes Private Placement
September 12, 2013
Lorus Therapeutics Board of Directors Announces Review of Strategic Alternatives
July 15, 2013
Lorus Therapeutics Reports Results for Fiscal Year 2013
July 9, 2013
Lorus Therapeutics Announces Promising Clinical Results for Anticancer Drug LOR-253
June 27, 2013
Lorus Therapeutics Appoints Dr. Brad Thompson, an Experienced Biotechnology Professional, to the Board of Directors
June 19, 2013
Lorus Therapeutics Closes Private Placement
April 17, 2013
Lorus Therapeutics Signs Research and License Option Agreement with Elanco
April 12, 2013
Lorus Therapeutics Reports Third Quarter Results for Fiscal Year 2013
March 5, 2013
Lorus Therapeutics Announces Allowance of Chinese Patent for Anticancer Drug LOR-253
February 12, 2013
Lorus Therapeutics to Present LOR-253 Data at 2013 AACR Annual Meeting
January 22, 2013
Lorus Therapeutics Announces Issuance of United States Patent for Cancer Therapy IL-17E
January 14, 2013
Lorus Therapeutics Reports Second Quarter Results for Fiscal Year 2013
January 7, 2013
Lorus Therapeutics Announces Successful Dose Escalation of Its Phase I Clinical Trial of LOR-253 and Initiation of a Biomarker Clinical Study in Cancer Patients
December 18, 2012
Lorus Therapeutics and Brock University Sign Collaboration Agreement to Develop Novel Anticancer Drugs
December 4, 2012
Lorus Therapeutics Announces Positive Anticancer Data for IL-17E at AACR Tumor Immunology Conference
November 28, 2012
Lorus Therapeutics 2012 Annual and Special Meeting of Shareholders Announcement
November 27, 2012
Cancer Research UK and Lorus to Co-Develop First-Of-Kind Drug, IL-17E, to Treat Solid Tumours
October 15, 2012
Lorus Therapeutics Reports First Quarter Results for Fiscal 2013
October 3, 2012
Lorus Therapeutics to Present at BioContact 2012 in Quebec City
August 29, 2012
Lorus Therapeutics Receives Funding from the Government of Canada for Development of Cancer Therapy IL-17E
August 27, 2012
Lorus Therapeutics to Present at the 14th Annual Rodman & Renshaw Healthcare Conference in New York
August 26, 2012
Lorus Therapeutics Reports Results for Fiscal Year 2011
August 14, 2012
Lorus Therapeutics Announces Issuance of Patent in Japan for Anticancer Drug LOR-253 and Antimicrobial Drug LOR-220
August 8, 2012
Lorus Therapeutics Reports Results for Fiscal Year 2012
May 31, 2012
Lorus Therapeutics Announces Increase to Proposed Private Placement
May 8, 2012
Lorus Therapeutics Announces Proposed Private Placement
May 1, 2012
Lorus Therapeutics and Genentech Sign Global Intellectual Property License Agreement for IL-17E in Cancer
April 12, 2012
Lorus Therapeutics Reports Third Quarter Results for Fiscal Year 2012
April 11, 2012
Lorus Therapeutics Announces Allowance of United States Patent for Anticancer Drug LOR-253
April 3, 2012
Lorus Therapeutics Presents Positive Data for Lead Anticancer Drug LOR-253
March 27, 2012
Lorus Therapeutics Announces Positive Results from Its Small Molecule Antimicrobial Program
March 20, 2012
Lorus Therapeutics Announces Issuance of Patent for Anticancer Drug LOR-253 in Canada
January 13, 2012
Lorus Therapeutics Reports Second Quarter Results for Fiscal Year 2012
November 30, 2011
Lorus Therapeutics Provides Corporate Update
November 11, 2011
Lorus Therapeutics Reports First Quarter Results for Fiscal 2012
November 8, 2011
Lorus Therapeutics Presents Positive Data From Nonclinical Toxicity Studies on Lead Cancer Drug at Major Conference
September 27, 2011
Lorus Therapeutics Announces Allowance of Australian Patent for Clinical Cancer Drug LOR-253
August 15, 2011
Lorus Therapeutics Completes Unit Offering, Raising Approximately $2.2 Million
August 8, 2011
Lorus Therapeutics Provides Update on Offering of Units
July 22, 2011
Lorus Therapeutics Files Final Short Form Prospectus for Offering of Units
June 21, 2011
Lorus Therapeutics Files Preliminary Short Form Prospectus for Offering of Units
May 3, 2011
Lorus Therapeutics Announces Allowance of United States Patent for Cancer Drug LOR-2040 in the Treatment of Acute Myeloid Leukemia
April 12, 2011
Lorus Therapeutics Reports Third Quarter Results for Fiscal Year 2011
April 7, 2011
Lorus Therapeutics Appoints Warren Whitehead to Board of Directors
April 4, 2011
Lorus Therapeutics Announces Presentation of New Preclinical Data for Anticancer Drug LOR-253 at the American Association for Cancer Research Annual Meeting
February 22, 2011
Lorus Therapeutics Announces Publication on LOR-2040 Anticancer Activity in Acute Myeloid Leukemia
January 14, 2011
Lorus Therapeutics Reports Second Quarter Results for Fiscal Year 2011
January 13, 2011
Lorus Therapeutics Enrolls First Patient in Phase I Clinical Study of Anticancer Drug LOR-253